Evidence map›Paper›PMID 40337300›Full record

ArticleHemaSphere2025

Integration of gene mutations in risk prognostication for watch-and-wait follicular lymphoma patients initiating first-line treatment.

Tian-Yuan Xu, Rong-Ji Mu, Hui-Lai Zhang, Bing Xu, Rong Li, Nan Wang, Rui Sun, Rui-Chi Li, Di Fu, Xian-Huo Wang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tian-Yuan XuShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Rong-Ji MuClinical Research Institute Shanghai Jiao Tong University School of Medicine Shanghai China.
Hui-Lai ZhangDepartment of Lymphoma Tianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research Tianjin China.
Bing XuDepartment of Hematology The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University Xiamen China.
Rong LiDepartment of Hematology, Navy Medical Center of PLA Naval Medical University Changning District Shanghai China.
Nan WangShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Rui SunShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Rui-Chi LiShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Di FuShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Xian-Huo WangClinical Research Institute Shanghai Jiao Tong University School of Medicine Shanghai China.ORCID 0000-0002-7663-2923
Zhi-Feng LiDepartment of Lymphoma Tianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research Tianjin China.
Yan ZhaoShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Peng-Peng XuShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Shu ChengShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Li WangShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Wei TangShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Zhong ZhengShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
Wei-Li ZhaoShanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.ORCID 0000-0002-6834-1616

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Follicular lymphoma (FL) patients with low tumor burden at diagnosis frequently undergo the watch-and-wait (W&W) strategy. The study aimed to facilitate risk assessment in predicting the time to lymphoma treatment (TLT) for W&W patients through an integrated analysis of clinical factors and genetic mutations. A retrospective study was conducted on 214 FL patients managed with W&W between 2016 and 2023. Among them, 184 patients underwent targeted sequencing. The median follow-up was 30.4 months (IQR 21.4-41.9, range 6.4-95.8). A clinico-genetic model m3-PRIMA-PI was developed using the multivariate Cox proportional hazards method, incorporating two clinical parameters (bone marrow involvement and elevated β2-MG) and three gene mutations (

Identifiers

PMID40337300
PMCPMC12056600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.